http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 29 Jun 2026 09:12:27 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/Canaccord+Reiterates+Buy+Rating+on+Artivion+Inc.+%28AORT%29/26703058.html <p>Canaccord analyst William Plovanic reiterated a Buy rating and $36.00 price target on Artivion Inc. (NYSE: AORT).</p><p>The analyst commented: "This morning, Artivion announced that its AMDS Hybrid Prosthesis received FDA premarket approval. The approval supports marketing for acute Debakey Type I aortic dissections with either clinical or radiographic malperfusion. Artivion estimates that this indication represents 60% of all Debakey Type I aortic dissection, which impacts ~6,000 U.S. patients annually, and is an emergent, life-threatening, surgery-requiring condition. Additionally, the approval also broadens AMDS’ label from the Humanitarian Device Exemption (“HDE” -see more below); previously, under the HDE, AMDS was only indicated http://www.streetinsider.com/Analyst+Comments/Canaccord+Reiterates+Buy+Rating+on+Artivion+Inc.+%28AORT%29/26703058.html Mon, 29 Jun 2026 09:12:27 -0400 AORT http://www.streetinsider.com/FDA/FDA+approves+Artivion%27s+AMDS+device+for+aortic+dissection+treatment/26701917.html <p>Artivion, Inc. (NYSE: AORT) announced that the U.S. Food and Drug Administration has approved the premarket approval application (PMA) for its AMDS Hybrid Prosthesis, a device used in the treatment of acute DeBakey Type I aortic dissections with clinical or radiographic malperfusion.</p> <p>The approval covers an estimated 60% of all DeBakey Type I aortic dissection cases. With the PMA in place, hospitals will no longer need to obtain institutional review board approval before implanting the device, a requirement that had been tied to its prior Humanitarian Device Exemption status.</p> <p>The PMA is based on data from the PERSEVERE U.S. IDE trial, which http://www.streetinsider.com/FDA/FDA+approves+Artivion%27s+AMDS+device+for+aortic+dissection+treatment/26701917.html Mon, 29 Jun 2026 07:02:17 -0400 A.06822034 AORT O.00068416 O.20026344 http://www.streetinsider.com/FDA/FDA+approves+Artivion%27s+AMDS+device+for+aortic+dissection+treatment/26701917.html <p>Artivion, Inc. (NYSE: AORT) announced that the U.S. Food and Drug Administration has approved the premarket approval application (PMA) for its AMDS Hybrid Prosthesis, a device used in the treatment of acute DeBakey Type I aortic dissections with clinical or radiographic malperfusion.</p> <p>The approval covers an estimated 60% of all DeBakey Type I aortic dissection cases. With the PMA in place, hospitals will no longer need to obtain institutional review board approval before implanting the device, a requirement that had been tied to its prior Humanitarian Device Exemption status.</p> <p>The PMA is based on data from the PERSEVERE U.S. IDE trial, which http://www.streetinsider.com/FDA/FDA+approves+Artivion%27s+AMDS+device+for+aortic+dissection+treatment/26701917.html Mon, 29 Jun 2026 07:02:17 -0400 A.06822034 AORT O.00068416 O.20026344 http://www.streetinsider.com/FDA/FDA+approves+Artivion%27s+AMDS+device+for+aortic+dissection+treatment/26701917.html <p>Artivion, Inc. (NYSE: AORT) announced that the U.S. Food and Drug Administration has approved the premarket approval application (PMA) for its AMDS Hybrid Prosthesis, a device used in the treatment of acute DeBakey Type I aortic dissections with clinical or radiographic malperfusion.</p> <p>The approval covers an estimated 60% of all DeBakey Type I aortic dissection cases. With the PMA in place, hospitals will no longer need to obtain institutional review board approval before implanting the device, a requirement that had been tied to its prior Humanitarian Device Exemption status.</p> <p>The PMA is based on data from the PERSEVERE U.S. IDE trial, which http://www.streetinsider.com/FDA/FDA+approves+Artivion%27s+AMDS+device+for+aortic+dissection+treatment/26701917.html Mon, 29 Jun 2026 07:02:17 -0400 A.06822034 AORT O.00068416 O.20026344 http://www.streetinsider.com/FDA/FDA+approves+Artivion%27s+AMDS+device+for+aortic+dissection+treatment/26701917.html <p>Artivion, Inc. (NYSE: AORT) announced that the U.S. Food and Drug Administration has approved the premarket approval application (PMA) for its AMDS Hybrid Prosthesis, a device used in the treatment of acute DeBakey Type I aortic dissections with clinical or radiographic malperfusion.</p> <p>The approval covers an estimated 60% of all DeBakey Type I aortic dissection cases. With the PMA in place, hospitals will no longer need to obtain institutional review board approval before implanting the device, a requirement that had been tied to its prior Humanitarian Device Exemption status.</p> <p>The PMA is based on data from the PERSEVERE U.S. IDE trial, which http://www.streetinsider.com/FDA/FDA+approves+Artivion%27s+AMDS+device+for+aortic+dissection+treatment/26701917.html Mon, 29 Jun 2026 07:02:17 -0400 A.06822034 AORT O.00068416 O.20026344 http://www.streetinsider.com/Press+Releases/Artivion+Announces+U.S.+FDA+Approval+of+the+AMDS+Hybrid+Prosthesis/26701845.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>June 29, 2026</chron></span> /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has approved the premarket approval application (PMA) for the AMDS Hybrid Prosthesis ("AMDS"). The approval covers acute Debakey Type I aortic dissections with either clinical or radiographic malperfusion, which the Company estimates to be approximately 60% of all Debakey Type I aortic dissections. Given this approval, hospitals will no longer be required to obtain institutional review board (IRB) approval in order http://www.streetinsider.com/Press+Releases/Artivion+Announces+U.S.+FDA+Approval+of+the+AMDS+Hybrid+Prosthesis/26701845.html Mon, 29 Jun 2026 07:00:00 -0400 A.06822034 AORT O.00068416 O.20026344 http://www.streetinsider.com/Press+Releases/Artivion+Announces+U.S.+FDA+Approval+of+the+AMDS+Hybrid+Prosthesis/26701845.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>June 29, 2026</chron></span> /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has approved the premarket approval application (PMA) for the AMDS Hybrid Prosthesis ("AMDS"). The approval covers acute Debakey Type I aortic dissections with either clinical or radiographic malperfusion, which the Company estimates to be approximately 60% of all Debakey Type I aortic dissections. Given this approval, hospitals will no longer be required to obtain institutional review board (IRB) approval in order http://www.streetinsider.com/Press+Releases/Artivion+Announces+U.S.+FDA+Approval+of+the+AMDS+Hybrid+Prosthesis/26701845.html Mon, 29 Jun 2026 07:00:00 -0400 A.06822034 AORT O.00068416 O.20026344 http://www.streetinsider.com/Press+Releases/Artivion+Announces+U.S.+FDA+Approval+of+the+AMDS+Hybrid+Prosthesis/26701845.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>June 29, 2026</chron></span> /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has approved the premarket approval application (PMA) for the AMDS Hybrid Prosthesis ("AMDS"). The approval covers acute Debakey Type I aortic dissections with either clinical or radiographic malperfusion, which the Company estimates to be approximately 60% of all Debakey Type I aortic dissections. Given this approval, hospitals will no longer be required to obtain institutional review board (IRB) approval in order http://www.streetinsider.com/Press+Releases/Artivion+Announces+U.S.+FDA+Approval+of+the+AMDS+Hybrid+Prosthesis/26701845.html Mon, 29 Jun 2026 07:00:00 -0400 A.06822034 AORT O.00068416 O.20026344 http://www.streetinsider.com/Press+Releases/Artivion+Announces+U.S.+FDA+Approval+of+the+AMDS+Hybrid+Prosthesis/26701845.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>June 29, 2026</chron></span> /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has approved the premarket approval application (PMA) for the AMDS Hybrid Prosthesis ("AMDS"). The approval covers acute Debakey Type I aortic dissections with either clinical or radiographic malperfusion, which the Company estimates to be approximately 60% of all Debakey Type I aortic dissections. Given this approval, hospitals will no longer be required to obtain institutional review board (IRB) approval in order http://www.streetinsider.com/Press+Releases/Artivion+Announces+U.S.+FDA+Approval+of+the+AMDS+Hybrid+Prosthesis/26701845.html Mon, 29 Jun 2026 07:00:00 -0400 A.06822034 AORT O.00068416 O.20026344 http://www.streetinsider.com/PRNewswire/Artivion+Announces+U.S.+FDA+Approval+of+the+AMDS+Hybrid+Prosthesis/26701845.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>June 29, 2026</chron></span> /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has approved the premarket approval application (PMA) for the AMDS Hybrid Prosthesis ("AMDS"). The approval covers acute Debakey Type I aortic dissections with either clinical or radiographic malperfusion, which the Company estimates to be approximately 60% of all Debakey Type I aortic dissections. Given this approval, hospitals will no longer be required to obtain institutional review board (IRB) approval in order http://www.streetinsider.com/PRNewswire/Artivion+Announces+U.S.+FDA+Approval+of+the+AMDS+Hybrid+Prosthesis/26701845.html Mon, 29 Jun 2026 07:00:00 -0400 A.06822034 AORT O.00068416 O.20026344 http://www.streetinsider.com/PRNewswire/Artivion+Announces+U.S.+FDA+Approval+of+the+AMDS+Hybrid+Prosthesis/26701845.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>June 29, 2026</chron></span> /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has approved the premarket approval application (PMA) for the AMDS Hybrid Prosthesis ("AMDS"). The approval covers acute Debakey Type I aortic dissections with either clinical or radiographic malperfusion, which the Company estimates to be approximately 60% of all Debakey Type I aortic dissections. Given this approval, hospitals will no longer be required to obtain institutional review board (IRB) approval in order http://www.streetinsider.com/PRNewswire/Artivion+Announces+U.S.+FDA+Approval+of+the+AMDS+Hybrid+Prosthesis/26701845.html Mon, 29 Jun 2026 07:00:00 -0400 A.06822034 AORT O.00068416 O.20026344 http://www.streetinsider.com/PRNewswire/Artivion+Announces+U.S.+FDA+Approval+of+the+AMDS+Hybrid+Prosthesis/26701845.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>June 29, 2026</chron></span> /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has approved the premarket approval application (PMA) for the AMDS Hybrid Prosthesis ("AMDS"). The approval covers acute Debakey Type I aortic dissections with either clinical or radiographic malperfusion, which the Company estimates to be approximately 60% of all Debakey Type I aortic dissections. Given this approval, hospitals will no longer be required to obtain institutional review board (IRB) approval in order http://www.streetinsider.com/PRNewswire/Artivion+Announces+U.S.+FDA+Approval+of+the+AMDS+Hybrid+Prosthesis/26701845.html Mon, 29 Jun 2026 07:00:00 -0400 A.06822034 AORT O.00068416 O.20026344 http://www.streetinsider.com/PRNewswire/Artivion+Announces+U.S.+FDA+Approval+of+the+AMDS+Hybrid+Prosthesis/26701845.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>June 29, 2026</chron></span> /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has approved the premarket approval application (PMA) for the AMDS Hybrid Prosthesis ("AMDS"). The approval covers acute Debakey Type I aortic dissections with either clinical or radiographic malperfusion, which the Company estimates to be approximately 60% of all Debakey Type I aortic dissections. Given this approval, hospitals will no longer be required to obtain institutional review board (IRB) approval in order http://www.streetinsider.com/PRNewswire/Artivion+Announces+U.S.+FDA+Approval+of+the+AMDS+Hybrid+Prosthesis/26701845.html Mon, 29 Jun 2026 07:00:00 -0400 A.06822034 AORT O.00068416 O.20026344 http://www.streetinsider.com/Analyst+Comments/Canaccord+Reiterates+Buy+Rating+on+Artivion+Inc.+%28AORT%29/26650081.html <p>Canaccord analyst William Plovanic reiterated a Buy rating and $36.00 price target on Artivion Inc. (NYSE: AORT).</p><p>The analyst commented: "We recently went on the road with Pat Mackin, CEO and Lance Berry, CFO of Artivion. We hosted meetings with both existing investors and investors new to the name. As expected, most of the meetings focused on the guidance reset, how investors should think about the expected shortfall in AMDS for 2026 (is this an air pocket or structural issue?), the potential impact and timing for NEXUS, and future cash needs. In sum, we believe the messaging was that AMDS is http://www.streetinsider.com/Analyst+Comments/Canaccord+Reiterates+Buy+Rating+on+Artivion+Inc.+%28AORT%29/26650081.html Tue, 16 Jun 2026 06:36:50 -0400 AORT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ARTIVION%2C+INC.++++++++++++For%3A+Jun+11++Filed+by%3A+GREEN+ANDREW+M/26645950.html si-local-file:///var/storage/secattach/20260615/26645950.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ARTIVION%2C+INC.++++++++++++For%3A+Jun+11++Filed+by%3A+GREEN+ANDREW+M/26645950.html Mon, 15 Jun 2026 11:29:00 -0400 AORT O.00068416 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ARTIVION%2C+INC.++++++++++++For%3A+Jun+11++Filed+by%3A+GREEN+ANDREW+M/26645950.html si-local-file:///var/storage/secattach/20260615/26645950.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ARTIVION%2C+INC.++++++++++++For%3A+Jun+11++Filed+by%3A+GREEN+ANDREW+M/26645950.html Mon, 15 Jun 2026 11:29:00 -0400 AORT O.00068416 http://www.streetinsider.com/SEC+Filings/Form++144++++++++ARTIVION%2C+INC.+++++++++++++++++++++++++Filed+by%3A+GREEN+ANDREW+M/26636521.html si-local-file:///var/storage/secattach/20260611/26636521.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++ARTIVION%2C+INC.+++++++++++++++++++++++++Filed+by%3A+GREEN+ANDREW+M/26636521.html Thu, 11 Jun 2026 16:50:00 -0400 AORT O.00068416 http://www.streetinsider.com/SEC+Filings/Form++144++++++++ARTIVION%2C+INC.+++++++++++++++++++++++++Filed+by%3A+GREEN+ANDREW+M/26636521.html si-local-file:///var/storage/secattach/20260611/26636521.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++ARTIVION%2C+INC.+++++++++++++++++++++++++Filed+by%3A+GREEN+ANDREW+M/26636521.html Thu, 11 Jun 2026 16:50:00 -0400 AORT O.00068416 http://www.streetinsider.com/Press+Releases/Artivion+to+Participate+in+the+2026+Truist+Securities+MedTech+Conference/26629949.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>June 10, 2026</chron></span> /PRNewswire/ --<b> <span value="NYSE:AORT" idsrc="xmltag.org" >Artivion, Inc.</span> (NYSE: AORT),</b> a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate at the upcoming 2026 <span>Truist Securities MedTech Conference</span> on <chron>Tuesday, June 16, 2026</chron>, at the <location>Boston Harbor Hotel</location>. The Company's fireside chat is scheduled to begin at <chron>1:00 p.m. ET</chron> on <chron>Tuesday, June 16, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Artivion+to+Participate+in+the+2026+Truist+Securities+MedTech+Conference/26629949.html Wed, 10 Jun 2026 16:10:00 -0400 AORT O.00068416 http://www.streetinsider.com/Press+Releases/Artivion+to+Participate+in+the+2026+Truist+Securities+MedTech+Conference/26629949.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>June 10, 2026</chron></span> /PRNewswire/ --<b> <span value="NYSE:AORT" idsrc="xmltag.org" >Artivion, Inc.</span> (NYSE: AORT),</b> a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate at the upcoming 2026 <span>Truist Securities MedTech Conference</span> on <chron>Tuesday, June 16, 2026</chron>, at the <location>Boston Harbor Hotel</location>. The Company's fireside chat is scheduled to begin at <chron>1:00 p.m. ET</chron> on <chron>Tuesday, June 16, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Artivion+to+Participate+in+the+2026+Truist+Securities+MedTech+Conference/26629949.html Wed, 10 Jun 2026 16:10:00 -0400 AORT O.00068416 http://www.streetinsider.com/PRNewswire/Artivion+to+Participate+in+the+2026+Truist+Securities+MedTech+Conference/26629949.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>June 10, 2026</chron></span> /PRNewswire/ --<b> <span value="NYSE:AORT" idsrc="xmltag.org" >Artivion, Inc.</span> (NYSE: AORT),</b> a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate at the upcoming 2026 <span>Truist Securities MedTech Conference</span> on <chron>Tuesday, June 16, 2026</chron>, at the <location>Boston Harbor Hotel</location>. The Company's fireside chat is scheduled to begin at <chron>1:00 p.m. ET</chron> on <chron>Tuesday, June 16, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Artivion+to+Participate+in+the+2026+Truist+Securities+MedTech+Conference/26629949.html Wed, 10 Jun 2026 16:10:00 -0400 AORT O.00068416 http://www.streetinsider.com/PRNewswire/Artivion+to+Participate+in+the+2026+Truist+Securities+MedTech+Conference/26629949.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>June 10, 2026</chron></span> /PRNewswire/ --<b> <span value="NYSE:AORT" idsrc="xmltag.org" >Artivion, Inc.</span> (NYSE: AORT),</b> a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate at the upcoming 2026 <span>Truist Securities MedTech Conference</span> on <chron>Tuesday, June 16, 2026</chron>, at the <location>Boston Harbor Hotel</location>. The Company's fireside chat is scheduled to begin at <chron>1:00 p.m. ET</chron> on <chron>Tuesday, June 16, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Artivion+to+Participate+in+the+2026+Truist+Securities+MedTech+Conference/26629949.html Wed, 10 Jun 2026 16:10:00 -0400 AORT O.00068416 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++ARTIVION%2C+INC.++++++++++++For%3A+Jun+01++Filed+by%3A+GREEN+ANDREW+M/26618548.html si-local-file:///var/storage/secattach/20260608/26618548.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++ARTIVION%2C+INC.++++++++++++For%3A+Jun+01++Filed+by%3A+GREEN+ANDREW+M/26618548.html Mon, 08 Jun 2026 17:51:00 -0400 AORT O.00068416 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++ARTIVION%2C+INC.++++++++++++For%3A+Jun+01++Filed+by%3A+GREEN+ANDREW+M/26618548.html si-local-file:///var/storage/secattach/20260608/26618548.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++ARTIVION%2C+INC.++++++++++++For%3A+Jun+01++Filed+by%3A+GREEN+ANDREW+M/26618548.html Mon, 08 Jun 2026 17:51:00 -0400 AORT O.00068416 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ARTIVION%2C+INC.++++++++++++For%3A+Jun+02++Filed+by%3A+SEMEDO+ANTHONY+B./26606494.html si-local-file:///var/storage/secattach/20260604/26606494.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++ARTIVION%2C+INC.++++++++++++For%3A+Jun+02++Filed+by%3A+SEMEDO+ANTHONY+B./26606494.html Thu, 04 Jun 2026 16:50:00 -0400 AORT O.00068416